NCT04250051View on ClinicalTrials.gov

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

December 21, 2020

Primary Completion Date

January 8, 2025

Study Completion Date

December 1, 2028

Conditions
Recurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRecurrent Myeloproliferative NeoplasmRefractory Acute Myeloid LeukemiaRefractory Myelodysplastic Syndrome
Interventions
DRUG

Cytarabine

Given IV

BIOLOGICAL

Filgrastim

Given SC

DRUG

Fludarabine

Given IV

DRUG

Fludarabine Phosphate

Given IV

DRUG

Ivosidenib

Given PO

Trial Locations (1)

60611

Northwestern University, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER